EQS-News: IVRO Continues Drive to Minimize Unnecessary Live Animal Testing

PLACENTIA, CA - May 13, 2025 (NEWMEDIAWIRE) - Today, Invitro International (OTCQB: IVRO) reported first half FY '25 sales of $440,650, up 4.4% vs. the same period in FY '24. Net income of $49,239 declined from $65,345 (24.7%) for the same six months in FY '24, reflecting inflationary and OTCQB increased costs. 

CEO and Chairman, W. Richard Ulmer, enthused: "We believe IVRO's first half FY '25 indicates we may be entering a growth period for Non-Animal test technologies. Canada more recently passed legislation, now about to be joined by the U.S.A., follows Europe's 2013 ban on the introduction of new cosmetcs if they have been developed using animal tests. Our Congressional discussions in support have discussed even extending such a ban to include OTC shampoos and skin care products. Now would be an excellent time to mandate additional areas for Regulatory acceptance of scientifically proven invitro test methods."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially difference from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.

Company Contact:

W. Richard Ulmer, Chief Executive Officer and Chairman, (800) 246-8487, invitro@invitrointl.com